Contineum Therapeutics Issues Routine 14,750-Share Option Grant to Director

Rhea-AI Filing Summary

Form 4 Overview: On 06/26/2025, Contineum Therapeutics (CTNM) filed a Form 4 reporting that non-employee director Sarah Boyce received a stock option grant for 14,750 shares of the company’s Class A common stock at an exercise price of $4.01 per share. The option was issued under the company’s 2024 Equity Incentive Plan as part of the regular non-employee director compensation program.

Key Terms: The option vests in full on the earlier of (i) June 26, 2026 (one-year anniversary of the grant) or (ii) the next regular annual meeting of stockholders, provided Ms. Boyce remains a board member. It expires on 06/25/2035.

Post-Transaction Holdings: Following this transaction, Ms. Boyce beneficially owns 14,750 derivative securities (stock options) directly.

Investor Takeaway: The filing reflects routine director compensation and signals alignment of director incentives with shareholder value; financial impact and dilution are immaterial relative to typical public company share counts.

Positive

• Director received 14,750 stock options at $4.01, enhancing alignment with shareholders

Negative

• Grant introduces minor potential dilution of 14,750 shares

Insights

Securities Analyst

TL;DR: Routine director option grant; negligible dilution; neutral on valuation.

The grant of 14,750 options at $4.01 is standard board compensation and represents a very small fraction of typical biotech share counts, implying minimal dilution risk. No shares were bought or sold in the open market, so the transaction does not signal insider sentiment. Vesting over one year or at the next AGM maintains director alignment without creating immediate liquidity. Overall, the filing is administratively important but not expected to influence CTNM’s near-term share price.

Corporate Governance Specialist

TL;DR: Governance-aligned equity grant; standard practice; impact limited.

Contineum’s non-employee director program automatically grants options after each annual meeting, fostering governance best practices by tying director compensation to long-term performance. The one-year vesting and 10-year life are market-typical. Because the grant size is small and there are no accompanying sales, the disclosure is primarily procedural with no adverse governance implications.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boyce Sarah

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.01	06/26/2025		A		14,750		(1)	06/25/2035	Class A Common Stock	14,750	$0	14,750	D

Explanation of Responses:

1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

	/s/ Peter Slover, Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the CTNM Form 4 dated 06/26/2025 report?

Sarah Boyce was granted 14,750 stock options at an exercise price of $4.01.

How many Contineum Therapeutics shares are covered by the new options?

14,750 shares of Class A common stock.

When do the options awarded to Sarah Boyce vest?

They vest in full on 06/26/2026 or at the next annual meeting, whichever occurs first.

What is the expiration date of the granted stock options?

The options expire on 06/25/2035.

Does the filing indicate any purchase or sale of CTNM common shares?

No. The Form 4 only reports an option grant; no shares were bought or sold.